• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation.

作者信息

Giacalone Nicholas J, Niemierko Andrzej, Shipley William U, Efstathiou Jason A

机构信息

Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.

出版信息

Eur Urol. 2017 Sep;72(3):e64-e65. doi: 10.1016/j.eururo.2017.06.007. Epub 2017 Jun 19.

DOI:10.1016/j.eururo.2017.06.007
PMID:28642020
Abstract
摘要

相似文献

1
Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation.对赛义德·萨菲里和埃尔凡·阿尤比致编辑信的回复：关于尼古拉斯·J·贾卡洛内、威廉·U·希普利、丽贝卡·H·克莱曼等人的《肌肉浸润性膀胱癌患者保膀胱三联疗法的长期疗效：麻省总医院经验的最新分析》。《欧洲泌尿外科杂志》2017年；71卷：952 - 60页。避免误解的方法学问题。
Eur Urol. 2017 Sep;72(3):e64-e65. doi: 10.1016/j.eururo.2017.06.007. Epub 2017 Jun 19.
2
Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation.回复：尼古拉斯·J·贾卡洛内、威廉·U·希普利、丽贝卡·H·克莱曼等。肌肉浸润性膀胱癌患者膀胱保留三联疗法的长期疗效：麻省总医院经验的最新分析。《欧洲泌尿外科杂志》2017年；71:952 - 60：避免误解的方法学问题。
Eur Urol. 2017 Sep;72(3):e63. doi: 10.1016/j.eururo.2017.06.008. Epub 2017 Jun 23.
3
Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11.回复：杰森·A·埃夫斯塔西乌、达芙娜·Y·施皮格尔、威廉·U·希普利等。侵袭性膀胱癌综合治疗选择性膀胱保留的长期疗效：麻省总医院的经验。《欧洲泌尿外科杂志》2012年；61卷：705 - 11页
Eur Urol. 2012 Aug;62(2):e41; author reply e42. doi: 10.1016/j.eururo.2012.04.054. Epub 2012 May 8.
4
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.保留膀胱的三联疗法治疗肌层浸润性膀胱癌患者的长期疗效：马萨诸塞州综合医院经验的更新分析。
Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9.
5
Re: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013;63:823-9.回复：菲利普·J·格雷、斯泰西·A·费德瓦、威廉·U·希普利等人。美国肌肉浸润性膀胱癌的潜在治愈性疗法应用：来自国家癌症数据库的结果。《欧洲泌尿外科杂志》2013年；63卷：823 - 829页。
Eur Urol. 2013 Oct;64(4):e84-5. doi: 10.1016/j.eururo.2013.06.039. Epub 2013 Jul 2.
6
Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.对埃尔凡·阿尤比和赛义德·萨菲里致编辑的信的回复，主题为：R. 杰弗里·卡恩斯、沃莱克·乔恩、阿什利·E. 罗斯等人。用于预测具有不良病理特征男性前列腺癌特异性死亡率的基因组风险分类器的验证。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2017.03.036。方法学问题。
Eur Urol. 2017 Dec;72(6):e158-e159. doi: 10.1016/j.eururo.2017.05.030. Epub 2017 May 31.
7
Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?
Eur Urol. 2019 May;75(5):e138-e139. doi: 10.1016/j.eururo.2019.01.037. Epub 2019 Feb 1.
8
Reply to Santhanam Sundar's letter to the editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18.回复桑塔南·桑达尔致编辑的信：关于阿尔努尔夫·施滕茨尔、奈杰尔·C·考恩、玛丽亚·德·桑蒂斯等人的《肌肉浸润性和转移性膀胱癌的治疗：欧洲泌尿外科学会指南更新》。《欧洲泌尿外科杂志》2011年；59卷：1009 - 1018页。
Eur Urol. 2012 Aug;62(2):e45-6. doi: 10.1016/j.eururo.2012.04.042. Epub 2012 May 3.
9
Reply to Samuel Bishara and Jim Adshead's letter to the editor re: Brian J. Linder, Igor Frank, John C. Cheville, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013;63:839-45.对塞缪尔·比沙拉和吉姆·阿兹海德致编辑信件的回复，内容涉及：布莱恩·J·林德、伊戈尔·弗兰克、约翰·C·切维尔等人的《围手术期输血对根治性膀胱切除术后癌症复发和生存的影响》。《欧洲泌尿外科杂志》2013年；63卷：839 - 45页
Eur Urol. 2013 Sep;64(3):e49-50. doi: 10.1016/j.eururo.2013.05.058. Epub 2013 Jun 12.
10
Re: J. Alfred Witjes, Thierry Lebret, Eva M. Compérat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.回复：J. 阿尔弗雷德·维特耶斯、蒂埃里·勒布雷、伊娃·M. 孔佩拉特等。《2016年欧洲泌尿外科学会肌肉浸润性和转移性膀胱癌指南更新》。《欧洲泌尿外科杂志》2017年；71卷：462 - 475页。
Eur Urol. 2017 Aug;72(2):e45. doi: 10.1016/j.eururo.2017.02.031. Epub 2017 Mar 6.

引用本文的文献

1
Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer.高级别非肌层浸润性膀胱癌和局限性肌层浸润性膀胱癌的膀胱保留现状
Curr Oncol Rep. 2025 Apr 30. doi: 10.1007/s11912-025-01657-3.
2
Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes.夹作为新型的基准标记物在三联疗法保膀胱治疗肌层浸润性膀胱癌中的应用：可行性和患者预后。
Int Braz J Urol. 2021 Jan-Feb;47(1):93-99. doi: 10.1590/S1677-5538.IBJU.2019.0713.